The association between diabetes and prostate cancer has been inconsistently reported, even though two meta-analyses suggested that diabetic patients have a lower risk of prostate cancer of 9% ([@B1]) and 16% ([@B2]), respectively.

While the two meta-analyses were examined, many studies were case-control and only three focused on the follow-up of cohorts of diabetic patients ([@B3]--[@B5]). Among the three cohorts, the cases of prostate cancer were 9 ([@B3]), 498 ([@B4]), and 2,455 ([@B5]), respectively; and only the last ([@B5]) showed a significant 9% risk reduction in diabetic patients. Except for the first study being conducted in residents with diabetes in Rochester, Minnesota ([@B3]), the diabetic patients in the other two were from hospitalized patients in Denmark ([@B4]) and Sweden ([@B5]), respectively. The meta-analyses have limitations including a mixture of case-control and cohort designs, a mixture of incident and dead cases, a small number of prostate cancer in most studies, and different sources of subjects with potential selection bias. Although the contamination of type 1 diabetes is possibly minimal because \>90% of overall patients have type 2 diabetes, residual confounding could not be excluded if the two types of diabetes are not differentiated.

Although some recent studies still suggested a lower risk of prostate cancer in diabetic patients including Caucasians ([@B6],[@B7]), Iranians ([@B8]), Israelis ([@B9]), African Americans, Native Hawaiians, and Japanese Americans ([@B6]), the lower risk in African Americans and Native Hawaiians ([@B6]) was not significant. Two Japanese studies did not find any significant association ([@B10],[@B11]). The Ohsaki Cohort Study suggested that diabetes was not predictive for total prostate cancer, but diabetic patients did show a higher risk of advanced cancer ([@B11]).

Because diabetic patients are prone to develop cancer involving pancreas, liver, breast, colorectum, bladder, and endometrium ([@B12]--[@B15]) and the protective effect of diabetes on prostate cancer requires confirmation, this study evaluated the possible link between diabetes and prostate cancer, and the potential risk factors, by using the reimbursement database of the National Health Insurance (NHI) in Taiwan.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Study population {#s6}
----------------

According to the Ministry of Interior, \>98.0% of the Taiwanese population in 2005 (22,770,383: 11,562,440 men and 11,207,943 women) were covered by the NHI ([@B16]). A random sample of 1,000,000 subjects covered by the NHI in 2005 was created by the National Health Research Institute. The reimbursement databases were available back to 1996. Identification number, sex, birth date, and diagnostic codes based on the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) were retrieved. Diabetes was coded 250.1--250.9, and prostate cancer was coded 185.

Because prostate cancer is rare in young men, we analyzed the data for all ages and for those aged ≥40 years in the following groups: 40--64, 65--74, and ≥75 years (case number of prostate cancer was too small for age \<40 years). [Figure 1](#F1){ref-type="fig"} shows a flowchart for selecting cases for the study. After excluding women, type 1 diabetes (in Taiwan, patients with type 1 diabetes were issued a "Severe Morbidity Card" after certified diagnosis), living region unknown, and prostate cancer diagnosed before 2003, 494,630 men for all ages and 204,741 men ≥40 years old and without prostate cancer were followed from the beginning of 2003 to the end of 2005.

![Flowchart showing the procedures in the calculation of 3-year cumulative incidence of prostate cancer from 2003 to 2005.](616fig1){#F1}

Statistical analyses {#s7}
--------------------

The trends of crude and age-standardized (to the 2000 World Health Organization \[WHO\] population) incidence of prostate cancer in 1995--2006 in the general population were first calculated from the Taiwan Cancer Registry database ([@B17]). Linear regression evaluated whether the trends changed significantly, where the incidence was the dependent and the calendar year the independent variable.

The age-specific cumulative incidences from 2003 to 2005 in diabetic and nondiabetic men were calculated for all ages and age 40--64, 65--74, and ≥75 years. The numerator was the number of patients with a first diagnosis of prostate cancer within 2003--2005; and the denominator was the number of insurants in that specific age. The risk ratio between diabetic and nondiabetic men was calculated, and the 95% CI was estimated by Taylor series approximation ([@B18]). To minimize the possibility that diabetes might be caused by prostate cancer during a different period, several lag time sensitivity analyses were performed by excluding patients with diabetes duration of \<1, \<3, and \<5 years.

In Taiwan, the National Health Research Institute recommends yearly screening of prostate cancer by digital rectal examination and prostate-specific antigen (PSA) determination for men aged ≥50 years or ≥45 years for those with a family history. The PSA cutoff is set at 4.0 ng/mL. If either examination is abnormal, prostate biopsy guided by transrectal ultrasonography is recommended. The cancer detection rate under this guideline was much lower in Taiwan (0.96--1.3%) than in the Western countries (3--5%); and population-based PSA screening program is not considered as cost effective ([@B19]). Therefore PSA test is not paid by the NHI when used for screening purpose in clinical practice. To evaluate whether the use of PSA test differed between those with and without diabetes, χ^2^ test compared the frequency of PSA test in 2003--2005 by diabetes status among men for all ages and for age ≥40 years.

Logistic regression calculated the adjusted odds ratios (ORs). Prostate cancer was the dependent variable, and the independent variables included age (\<40, 40--64, 65--74, and ≥75 years), diabetes duration (nondiabetes, \<1, 1--3, 3--5, and ≥5 years), comorbidities, medications, living region, and occupation. The comorbidities (ICD-9-CM codes) included hypertension (401--405), chronic obstructive pulmonary disease (490--496, a surrogate for smoking), stroke (430--438), nephropathy (580--589), ischemic heart disease (410--414), peripheral arterial disease (250.7, 785.4, 443.81, 440--448), eye disease (250.5, 362.0, 369, 366.41, 365.44), obesity (278), and dyslipidemia (272.0--272.4). Medications included statin, fibrate, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker, calcium channel blocker, sulfonylurea, metformin, insulin, acarbose, pioglitazone, and rosiglitazone. Comorbidities and medications were counted only as they appeared before 2003 to assure temporal correctness of cause and effect (prostate cancer). The NHI insurants were classified according to occupation, and this served as a surrogate for socioeconomic status. The living region served as a surrogate for geographical distribution of some environmental exposure. Occupation was categorized as follows: I: civil servants, teachers, employees of governmental or private business, professionals, and technicians; II: people without particular employers, self-employed, or seamen; III: farmers or fishermen; and IV: low-income families supported by social welfare or veterans. Living region was categorized as Taipei, Northern, Central, Southern, and Kao-Ping and Eastern. The regressions were performed for all ages and for age ≥40 years, separately. Because earlier analyses showed a significantly higher frequency of PSA test in the diabetic patients, additional logistic models were created by including PSA test as an additional independent variable to control for its potential confounding effect.

Analyses were conducted using SAS statistical software, version 9.1 (SAS Institute, Cary, NC). Data were expressed as mean (SD) for continuous variables or number (%) for categorical variables. *P* \< 0.05 was considered as statistically significant.

RESULTS {#s8}
=======

[Figure 2](#F2){ref-type="fig"} shows the crude and age-standardized incidence trends in the general population. Both are increasing significantly (*P* \< 0.0001).

![Trends of prostate cancer incidence in the general population of Taiwan from 1995 to 2006 (♦, crude rate; ![](616inf1.jpg), age-standardized rate using the 2000 WHO population as referent). (A high-quality color representation of this figure is available in the online issue.)](616fig2){#F2}

[Table 1](#T1){ref-type="table"} shows the 3-year cumulative incidences and the risk ratios between the diabetic and nondiabetic men in different ages. The cumulative incidence markedly increased with age in either the diabetic or nondiabetic men. Risk ratio analysis showed that diabetic patients had a higher risk than nondiabetic men in all age groups. However, divergent associations with regard to age were noted: those in the youngest age of 40--64 years had the highest risk ratio, followed by those in the oldest of ≥75 years, and those aged 65--74 years had the lowest risk ratio.

###### 

Rates (per 100,000) and risk ratios of 3-year cumulative incidence of prostate cancer from 2003 to 2005 in diabetic and nondiabetic men by age

                                           Three-year cumulative incidence by age (years)                                           
  ---------------------------------------- ------------------------------------------------ ------------------- ------------------- -------------------
  Diabetes of any duration                                                                                                          
   Diabetic men                                                                                                                     
  *  n* of prostate cancer                 362                                              75                  120                 166
  *  n* of diabetic men                    52,133                                           26,476              9,959               8,715
    Rate in diabetic men                   694.38                                           283.28              1,204.94            1,904.76
   Nondiabetic men                                                                                                                  
  *  n* of prostate cancer                 527                                              174                 159                 181
  *  n* of nondiabetic men                 442,509                                          128,587             17,841              13,168
    Rate in nondiabetic men                119.09                                           135.32              891.21              1,374.54
   Risk ratio                              5.83 (5.10--6.66)                                2.09 (1.60--2.74)   1.35 (1.07--1.71)   1.39 (1.12--1.71)
  Excluding diabetes diagnosed \<1 year                                                                                             
   Diabetic men                                                                                                                     
  *  n* of prostate cancer                 342                                              67                  112                 162
  *  n* of diabetic men                    47,789                                           24,000              9,342               8,242
    Rate in diabetic men                   715.65                                           279.17              1,198.89            1,965.54
   Nondiabetic men                                                                                                                  
  *  n* of prostate cancer                 527                                              174                 159                 181
  *  n* of nondiabetic men                 442,509                                          128,587             17,841              13,168
    Rate in nondiabetic men                119.09                                           135.32              891.21              1,374.54
   Risk ratio                              6.01 (5.25--6.88)                                2.06 (1.56--2.73)   1.35 (1.06--1.71)   1.43 (1.16--1.76)
  Excluding diabetes diagnosed \<3 years                                                                                            
   Diabetic men                                                                                                                     
  *  n* of prostate cancer                 292                                              52                  96                  144
  *  n* of diabetic men                    39,014                                           19,064              8,005               7,238
    Rate in diabetic men                   748.45                                           272.77              1,199.25            1,989.50
   Nondiabetic men                                                                                                                  
  *  n* of prostate cancer                 527                                              174                 159                 181
  *  n* of nondiabetic men                 442,509                                          128,587             17,841              13,168
    Rate in nondiabetic men                119.09                                           135.32              891.21              1,374.54
   Risk ratio                              6.28 (5.45--7.25)                                2.02 (1.48--2.75)   1.35 (1.05--1.73)   1.45 (1.17--1.80)
  Excluding diabetes diagnosed \<5 years                                                                                            
   Diabetic men                                                                                                                     
  *  n* of prostate cancer                 233                                              40                  75                  118
  *  n* of diabetic men                    29,868                                           14,100              6,493               6,052
    Rate in diabetic men                   780.10                                           283.69              1,155.09            1,949.77
   Nondiabetic men                                                                                                                  
  *  n* of prostate cancer                 527                                              174                 159                 181
  *  n* of nondiabetic men                 442,509                                          128,587             17,841              13,168
    Rate in nondiabetic men                119.09                                           135.32              891.21              1,374.54
   Risk ratio                              6.55 (5.62--7.64)                                2.10 (1.49--2.95)   1.30 (0.99--1.70)   1.42 (1.13--1.79)

Diabetic patients did show a higher frequency in the use of PSA test in either the analysis for all ages or for age ≥40 years ([Table 2](#T2){ref-type="table"}).

###### 

Examination of PSA in 2003--2005 by status of diabetes for all ages and age ≥40 years in Taiwanese men

  Examination of PSA   Diabetes   *P* value                    
  -------------------- ---------- ----------- -------- ------- ----------
  All ages                                                     
   No                  441,829    99.85       51,662   99.10   \<0.0001
   Yes                 680        0.15        471      0.90    
  Age ≥40 years                                                
   No                  158,928    99.58       44,681   98.96   \<0.0001
   Yes                 668        0.42        469      1.04    

[Table 3](#T3){ref-type="table"} shows the results of the logistic regressions. The results were similar in models without (model I) or with (model II) PSA as an additional independent variable. In model II only the ORs for the different subgroups of diabetes duration and PSA test are shown. Age was a remarkable risk factor, and diabetes duration showed a nonlinear increase in the risk. Nephropathy, ischemic heart disease, dyslipidemia, living region, and occupation were significant, whereas chronic obstructive pulmonary disease was borderline significant. None of the medications was significant.

###### 

Mutually adjusted ORs for prostate cancer derived from cumulative incident cases from 2003 to 2005

  Variables                                                                            All ages                  Age ≥40 years                             
  ------------------------------------------------------------------------------------ ------------------------- --------------- ------------------------- ----------
  Model I                                                                                                                                                  
   Age, years                                                                                                                                              
    \<40                                                                               Referent                                                            
    40--64                                                                             30.25 (17.62--51.91)      \<0.0001        Referent                  
    65--74                                                                             164.57 (95.10--284.81)    \<0.0001        5.44 (4.50--6.58)         \<0.0001
    ≥75                                                                                239.01 (137.40--415.76)   \<0.0001        7.89 (6.45--9.67)         \<0.0001
   Diabetes duration, years vs. nondiabetics                                                                                                               
    \<1                                                                                1.25 (0.79--1.96)         0.3386          1.25 (0.80--1.96)         0.3352
    1--3                                                                               1.45 (1.08--1.95)         0.0130          1.43 (1.06--1.92)         0.0198
    3--5                                                                               1.40 (1.05--1.86)         0.0224          1.40 (1.05--1.87)         0.0218
    ≥5                                                                                 1.30 (1.06--1.60)         0.0129          1.30 (1.06--1.60)         0.0130
   Hypertension, yes vs. no                                                            1.12 (0.94--1.33)         0.2037          1.12 (0.94--1.34)         0.1922
   Chronic obstructive pulmonary disease, yes vs. no                                   1.15 (0.99--1.33)         0.0657          1.16 (1.00--1.34)         0.0535
   Stroke, yes vs. no                                                                  0.98 (0.81--1.17)         0.8004          0.98 (0.82--1.17)         0.8057
   Nephropathy, yes vs. no                                                             1.27 (1.04--1.53)         0.0172          1.27 (1.05--1.54)         0.0161
   Ischemic heart disease, yes vs. no                                                  1.29 (1.09--1.52)         0.0026          1.28 (1.08--1.51)         0.0035
   Peripheral arterial disease, yes vs. no                                             0.95 (0.74--1.21)         0.6606          0.95 (0.74--1.21)         0.6595
   Eye disease, yes vs. no                                                             1.21 (0.84--1.75)         0.3161          1.21 (0.84--1.75)         0.3123
   Obesity, yes vs. no                                                                 0.80 (0.26--2.51)         0.7037          0.81 (0.26--2.55)         0.7228
   Dyslipidemia, yes vs. no                                                            1.42 (1.19--1.70)         0.0001          1.41 (1.18--1.69)         0.0002
   Statin, yes vs. no                                                                  1.14 (0.90--1.46)         0.2760          1.15 (0.90--1.47)         0.2567
   Fibrate, yes vs. no                                                                 0.93 (0.73--1.19)         0.5782          0.94 (0.74--1.19)         0.5897
   Angiotensin-converting enzyme inhibitor/angiotensin  receptor blocker, yes vs. no   1.07 (0.86--1.34)         0.5422          1.07 (0.86--1.34)         0.5427
   Calcium channel blocker, yes vs. no                                                 0.91 (0.72--1.15)         0.4299          0.91 (0.72--1.15)         0.4274
   Sulfonylurea, yes vs. no                                                            1.07 (0.78--1.46)         0.6873          1.07 (0.78--1.46)         0.6903
   Metformin, yes vs. no                                                               0.79 (0.56--1.11)         0.1796          0.79 (0.56--1.11)         0.1781
   Insulin, yes vs. no                                                                 0.52 (0.21--1.27)         0.1501          0.51 (0.21--1.27)         0.1481
   Acarbose, yes vs. no                                                                1.00 (0.49--2.02)         0.9901          1.00 (0.49--2.02)         0.9905
   Pioglitazone, yes vs. no                                                            0.77 (0.10--5.75)         0.7955          0.77 (0.10--5.77)         0.7979
   Rosiglitazone, yes vs. no                                                           0.88 (0.43--1.80)         0.7180          0.88 (0.43--1.80)         0.7206
   Living region                                                                                                                                           
    Northern vs. Taipei                                                                0.83 (0.68--1.01)         0.0604          0.84 (0.69--1.02)         0.0756
    Central vs. Taipei                                                                 0.66 (0.54--0.81)         \<0.0001        0.68 (0.56--0.83)         0.0002
    Southern vs. Taipei                                                                0.44 (0.35--0.57)         \<0.0001        0.46 (0.36--0.58)         \<0.0001
    Kao-Ping and Eastern vs. Taipei                                                    0.48 (0.39--0.60)         \<0.0001        0.49 (0.40--0.61)         \<0.0001
   Occupation                                                                                                                                              
    II vs. I                                                                           0.67 (0.52--0.86)         0.0015          0.68 (0.53--0.88)         0.0028
    III vs. I                                                                          0.78 (0.64--0.95)         0.0126          0.77 (0.63--0.94)         0.0116
    IV vs. I                                                                           0.83 (0.70--0.99)         0.0370          0.84 (0.71--0.99)         0.0475
  Model II[\*](#t3n1){ref-type="table-fn"}                                                                                                                 
   Diabetes duration, years vs. nondiabetics                                                                                                               
    \<1                                                                                1.207 (0.766--1.904)      0.4175          1.209 (0.767--1.907)      0.4139
    1--3                                                                               1.410 (1.046--1.900)      0.0242          1.381 (1.022--1.866)      0.0357
    3--5                                                                               1.387 (1.036--1.857)      0.0278          1.389 (1.038--1.859)      0.0270
    ≥5                                                                                 1.266 (1.028--1.559)      0.0267          1.266 (1.027--1.559)      0.0269
   PSA test, yes vs. no                                                                13.490 (10.899--16.697)   \<0.0001        13.374 (10.799--16.563)   \<0.0001

Refer to [[research design and methods]{.smallcaps}](#s2){ref-type="sec"} for the categories of occupation.

\*Model II: additionally adjusted for PSA test; only the ORs for diabetes duration and PSA test are shown.

CONCLUSIONS {#s9}
===========

The trends of prostate cancer were increasing significantly in 1995--2006 ([Fig. 2](#F2){ref-type="fig"}), and diabetes was associated with an increased risk at any duration ([Tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}), with the highest risk ratio observed in the youngest age of 40--64 years ([Table 1](#T1){ref-type="table"}).

Although some recent studies still favored a protective effect of diabetes in Caucasians ([@B6],[@B7]), a recent population-based case-control study in the US concluded that diabetes was not associated with prostate cancer (OR = 0.98, 95% CI: 0.76--1.27) and that the protective effect of diabetes might be because of a confounding of a mixture with type 1 diabetes ([@B20]). In the current study, patients with type 1 diabetes were excluded and its confounding is minimal.

Diabetes was unlikely caused by prostate cancer, because the association was consistent in different analyses ([Table 1](#T1){ref-type="table"}). Diabetes diagnosed 5 years before prostate cancer can hardly be a consequence of the carcinogenic process. Another possibility for an increased incidence in the diabetic patients is because of screening bias ([Table 2](#T2){ref-type="table"}). However, our analysis did not support such a possibility because the conclusions remained the same when PSA test was also included in the logistic analyses (model II of [Table 3](#T3){ref-type="table"}).

Heterogeneity may exist in the association between diabetes and prostate cancer. Some suggested that recent-onset diabetes may increase, but long-standing diabetes might reduce the risk ([@B21]). In the current study, although prostate cancer risk increased with increasing diabetes duration in unadjusted models (data not shown), the adjusted models showed that the highest risk was observed at diabetes duration of 1--3 years and then declined gradually ([Table 3](#T3){ref-type="table"}). Recently serum creatinine is shown to be significantly predictive for prostate cancer risk ([@B22]). Our finding of a significantly higher risk of 27% in patients with nephropathy ([Table 3](#T3){ref-type="table"}) confirmed such an observation. Some suggested that patients with more severe diabetes might have lower level of PSA and lower risk of prostate cancer ([@B23]). However, the current study showing a higher risk of prostate cancer associated with nephropathy, ischemic heart disease, and dyslipidemia ([Table 3](#T3){ref-type="table"}) argued against a simple scenario. With increasing duration and severity of diabetes, chronic complications may set in and interfere with the association between diabetes and prostate cancer. Some suggested that diabetes might only convey a higher risk of more advanced prostate cancer ([@B11],[@B24]). However, we did not have sufficient information for analysis.

It is interesting to observe an effect modification by age with the highest risk ratio observed at the youngest age of 40--64 years ([Table 1](#T1){ref-type="table"}). One explanation is that a higher mortality from other causes in the older diabetic patients before the development of prostate cancer may obscure the relationship, as opposed to the youngest age group who might have been exposed to inflammatory and carcinogenic effects of diabetes for a longer period of time. Such a relationship simply might not have been captured by case-control designs.

Some commonly used medications did not affect the risk ([Table 3](#T3){ref-type="table"}). However, geographical distribution and socioeconomic status, as indicated by living region and occupation, respectively, did significantly impact the risk ([Table 3](#T3){ref-type="table"}). People living in metropolitan Taipei region had the highest risk, and the risk seemed to decline gradually with lesser urbanization as shown from the ORs, much deviating from unity from Northern to Central, Southern, and Kao-Ping and Eastern region ([Table 3](#T3){ref-type="table"}). People with a higher socioeconomic status as indicated by occupation I also suffered from a higher risk ([Table 3](#T3){ref-type="table"}). The reasons for such discrepancy with regard to geographical distribution and socioeconomic status await further exploration.

This study has several strengths. It is population based with a large nationally representative sample. The database included outpatients and inpatients, and we caught the diagnoses from both sources. Cancer is considered as a severe morbidity by the NHI, and most medical copayments can be waived. Therefore the detection rate would not tend to differ among different social classes. The use of medical record also reduced the potential bias related to self-reporting.

Limitations included a lack of actual measurement of confounders such as obesity, smoking, alcohol drinking, family history, lifestyle, diet, hormones, and genetic parameters. In addition, we did not have biochemical data for evaluating their impact. Finally, the follow-up interval is probably too short to plausibly account for the likely induction time needed between the onset of diabetes and the biological changes leading to prostate cancer.

In summary, this study shows an increasing trend of prostate cancer in Taiwan and a link between diabetes and prostate cancer, which is more remarkable in the age of 40--64 years. Therefore, the observation that diabetes confers a lower risk of prostate cancer might not be universal. Insulin or other oral antidiabetic agents are not, but nephropathy, ischemic heart disease, and dyslipidemia are significantly associated with prostate cancer. The association between prostate cancer and these comorbidities suggests a more complicated scenario in the link between prostate cancer and diabetes at different disease stages. Given that the population is aging, the incidence of prostate cancer is increasing, and the incidence of type 2 diabetes is also increasing ([@B25]). The impact of prostate cancer on the population should warrant public health attention.
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